Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 642-645

  Rajagopalan, Prabhu ^a   Boudinot, F Douglas ^a   Chu, Chung K ^a   Tennant, Bud C ^b   Baldwin, Betty H ^b   Schinazi, Raymond F ^c,d  

^a UNIVERSITY OF GEORGIA   (United States)

^b Cornell University ^*  (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; WOODCHUCK;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAVENOUS; LAMIVUDINE; MALE; MARMOTA;

EID: 0030050719     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.642     Document Type: Article

References (32)

1. Benhamou, Y., E. Dohin, F. L. Fabiani, T. Poynard, J. M. Huraux, C. Katlama, P. Opolon, and M. Gentilini. 1995. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345:396-397.
2. Blaney, S. M., M. J. Daniel, A. J. Harker, K. Godwin, and F. M. Balis. 1995. Pharmacokinetics of limivudien and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates Antimicrob. Agents Chemother 39:2779-2782
3. Boxenbaum, H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan for pharmacokinetics. J Pharmacokinet. Biopharm. 10:201-227.
4. Bullard, R. W., and G. E. Funkhouser. 1962. Estimated regional blood flow by rubidium 86 distribution during arousal from hibernation. Am. J. Physiol 203:266-270.
5. Cammack, N., P. Rouse, C. L. P. Marr, P. J. Reid, R. E. Boehme, A. V. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
6. Chang, C. N., S. L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C. H. Tsai, and Y. C. Cheng. 1992 Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol. Chem. 267:13938-13942
7. Chen, H. S., S. Kaneko, R. Girones, R. W. Anderson, W. E. Hornbuckle, B. C. Tennant, P. J. Cote, J. L. Gerin, R. H. Purcell, and R. H. Miller. 1993 The woodchuck hepatitis virus X gene is important in the establishment of virus infection in woodchucks. J. Virol. 67:1218-1226.
8. Choi, W.-B., L. J. Wilson, S. Yeola, D. C. Liotta, and R. F. Schinazi. 1991. In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogues. J. Am. Chem. Soc. 113:9377-9379.
9. Coates, J. A., N. Cainmick, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
10. Fourel, I., O. Hantz, K. A. Watanabe, C. Jacquet, B. Chomel, J. J. Fox, and C. Trepo. 1990. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis B virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother 34:473-475.
11. Galibert, F., T. V. Chen, and E. Mandart. 1981. Localization and nucleotide sequence of the gene coding for the woodchuck hepatitis virus surface antigen: comparison with the gene coding for the human hepatitis B virus surface antigen. Proc. Natl. Acad. Sci USA 78:5315-5319.
12. Hantz, O., T. Oka, L. Vitvitski, C. Pichoud, and C. Trepo. 1984. Comparison of properties of woodchuck hepatitis virus and human virus endogenous DNA polymerases. Antimicrob. Agents Chemother 25:242-246.
13. Hong, S. K. 1957. Renal function during hypothermia and hibernation. Am. J. Physiol. 188:137-150.
14. Hoong, L. K., L. E. Stange, D. C. Liotta, G. W. Koszalka, C. L. Burns, and R. F. Schinazi. 1992. Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC) and related compounds. J. Org. Chem. 57:5563-5565.
15. Hussey, E. K., K. H. Donn, M. J. Daniel, S. T. Hall, A. J. Harker, and G. L. Evans. 1994. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J. Clin. Pharmacol. 34:975-977.
16. Ibrahim, S. S., and F. D. Boudinot. 1989. Pharmacokinetics of 2′,3′-dideoxycytidine in rats: application to interspecies scale-up. J. Pharm. Pharmacol. 41:829-834.
17. Ikeda, N., S. Kaneko, A. Shimoda, Y. Inagaki, M. Unoura, M. Okada, Y. Yonekawa, K. Takahashi, and K. Kobayashi. 1994. Efficiency of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus. J. Antimicrob. Chemother. 33:83-89.
18. Metzler, D. M., G. L. Elfring, and A. J. McEwen. 1974. NONLIN, a computer program for nonlinear least-squares regression. Biometrics 30:562-563.
19. Millman, I., T. Halbherr, and H. Simmons. 1982. Immunological cross-reactivities of woodchuck and hepatitis B viral antigens. Infect. Immun. 35:752-757.
20. 19a National Institutes of Health. 1985. Guide for the care and use of laboratory animals. National Institutes of Health, Rockville, Md.
21. Patel, B. A., F. D. Boudinot, R. F. Schinazi, J. M. Gallo, and C. K. Chu. 1990. Comparative pharmacokinetics and interspecies scaling of 3′-azido-3′-deoxythymidine (AZT) in several mammalian species J. Pharmacobiodyn. 13:206-211.
22. Rajagopalan, P., L. Moore, C. K. Chu, R. F. Schinazi, and F. D. Boudinot. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in rats. Submitted for publication.
23. Riggs, D. S., J. A. Guarnieri, and S. Addelman. 1978. Fitting straight lines when both variables are subject to error. Life Sci 22:1305-1360.
24. Rocci, M. L., and W. J. Jusko. 1983 LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed. 16:203-216.
25. Schinazi, R. F., R. M. Lloyd, Jr., M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathilanecytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
26. Snyder, R. L. 1985. The laboratory woodchuck. Lab. Anim. 14:20-32.
27. Snyder, R. L., and H. L. Ratcliffe. 1969. Marmota monax: & model for studies of cardiovascular, cerebrovascular and neoplastic disease Acta Zool Pathol. Antverp 48:265-273
28. Summers, J., J. M. Smolec, and R. Snyder. 1978. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. Natl Acad. Sci. USA 75:4533-4537
29. Tyrell, D. L. J., M. C. Mitchell, R. A. Deman, S. W. Schalm, J. Main, H. C. Thomas, J. Fevery, F. Nevens, P. Beranek, and C. Vicary. 1993. Phase II trial of lamivudine for chronic hepatitis-B. Hepatology 18:A112
30. van Leeuwen, R., C. Katlama, V. Kitchen, C. A. B. Boucher, R. Tubiana, M. Mcbride, D. Ingrand, J. Weber, A. Hill, H. Mcdade, and S. A. Danner. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symtomatic human-immunodeficiency-virus infectionphase I/II study. J. Infect. Dis. 171:1166-1171.
31. van Leeuwen, R., J. M. A. Lange, E. K. Hussey, K. H. Donn, S. T. Hall, A. J. Harker, P. Jonker, and S. A. Donner. 1992. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: phase I study. AIDS 6:1471-1475.
32. Werner, B. G., J. M. Smolec, R. Snyder, and J. Summers. 1979. Serological relationship of woodchuck hepatitis virus to human hepatitis B virus. J. Virol. 32:314-322